Structure-activity relationships of rationally designed AMACR 1A inhibitors

Maksims Jevglevskis, Guat Ling Lee, Amit Nathubhai, Yoana Petrova, Tony James, Michael Threadgill, Timothy Woodman, Matthew Lloyd

Research output: Contribution to journalArticle

2 Citations (Scopus)
6 Downloads (Pure)

Abstract

α-Methylacyl-CoA racemase (AMACR; P504S) is a promising novel drug target for prostate and other cancers. Assaying enzyme activity is difficult due to the reversibility of the ‘racemisation’ reaction and the difficulties in the separation of epimeric products; consequently few inhibitors have been described and no structure–activity relationship study has been performed. This paper describes the first structure–activity relationship study, in which a series of 23 known and potential rational AMACR inhibitors were evaluated. AMACR was potently inhibited (IC 50 = 400–750 nM) by ibuprofenoyl-CoA and derivatives. Potency was positively correlated with inhibitor lipophilicity. AMACR was also inhibited by straight-chain and branched-chain acyl-CoA esters, with potency positively correlating with inhibitor lipophilicity. 2-Methyldecanoyl-CoAs were ca. 3-fold more potent inhibitors than decanoyl-CoA, demonstrating the importance of the 2-methyl group for effective inhibition. Elimination substrates and compounds with modified acyl-CoA cores were also investigated, and shown to be potent inhibitors. These results are the first to demonstrate structure–activity relationships of rational AMACR inhibitors and that potency can be predicted by acyl-CoA lipophilicity. The study also demonstrates the utility of the colorimetric assay for thorough inhibitor characterisation.

Original languageEnglish
Pages (from-to)145-154
Number of pages10
JournalBioorganic and Medicinal Chemistry
Volume79
Early online date30 Apr 2018
DOIs
Publication statusPublished - 1 Sep 2018

Fingerprint

Acyl Coenzyme A
Enzyme activity
Coenzyme A
Assays
Esters
Derivatives
Substrates
Pharmaceutical Preparations

Keywords

  • Drug lipophilicity
  • Enzyme inhibitors
  • Rational drug design
  • Structure-activity relationships
  • α-Methylacyl-CoA racemase (AMACR, P504S)

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Organic Chemistry

Cite this

Structure-activity relationships of rationally designed AMACR 1A inhibitors. / Jevglevskis, Maksims; Lee, Guat Ling; Nathubhai, Amit; Petrova, Yoana; James, Tony; Threadgill, Michael; Woodman, Timothy; Lloyd, Matthew.

In: Bioorganic and Medicinal Chemistry, Vol. 79, 01.09.2018, p. 145-154.

Research output: Contribution to journalArticle

@article{c248b8b8deae443396d9c65410d2b129,
title = "Structure-activity relationships of rationally designed AMACR 1A inhibitors",
abstract = "α-Methylacyl-CoA racemase (AMACR; P504S) is a promising novel drug target for prostate and other cancers. Assaying enzyme activity is difficult due to the reversibility of the ‘racemisation’ reaction and the difficulties in the separation of epimeric products; consequently few inhibitors have been described and no structure–activity relationship study has been performed. This paper describes the first structure–activity relationship study, in which a series of 23 known and potential rational AMACR inhibitors were evaluated. AMACR was potently inhibited (IC 50 = 400–750 nM) by ibuprofenoyl-CoA and derivatives. Potency was positively correlated with inhibitor lipophilicity. AMACR was also inhibited by straight-chain and branched-chain acyl-CoA esters, with potency positively correlating with inhibitor lipophilicity. 2-Methyldecanoyl-CoAs were ca. 3-fold more potent inhibitors than decanoyl-CoA, demonstrating the importance of the 2-methyl group for effective inhibition. Elimination substrates and compounds with modified acyl-CoA cores were also investigated, and shown to be potent inhibitors. These results are the first to demonstrate structure–activity relationships of rational AMACR inhibitors and that potency can be predicted by acyl-CoA lipophilicity. The study also demonstrates the utility of the colorimetric assay for thorough inhibitor characterisation.",
keywords = "Drug lipophilicity, Enzyme inhibitors, Rational drug design, Structure-activity relationships, α-Methylacyl-CoA racemase (AMACR, P504S)",
author = "Maksims Jevglevskis and Lee, {Guat Ling} and Amit Nathubhai and Yoana Petrova and Tony James and Michael Threadgill and Timothy Woodman and Matthew Lloyd",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.bioorg.2018.04.024",
language = "English",
volume = "79",
pages = "145--154",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier",

}

TY - JOUR

T1 - Structure-activity relationships of rationally designed AMACR 1A inhibitors

AU - Jevglevskis, Maksims

AU - Lee, Guat Ling

AU - Nathubhai, Amit

AU - Petrova, Yoana

AU - James, Tony

AU - Threadgill, Michael

AU - Woodman, Timothy

AU - Lloyd, Matthew

PY - 2018/9/1

Y1 - 2018/9/1

N2 - α-Methylacyl-CoA racemase (AMACR; P504S) is a promising novel drug target for prostate and other cancers. Assaying enzyme activity is difficult due to the reversibility of the ‘racemisation’ reaction and the difficulties in the separation of epimeric products; consequently few inhibitors have been described and no structure–activity relationship study has been performed. This paper describes the first structure–activity relationship study, in which a series of 23 known and potential rational AMACR inhibitors were evaluated. AMACR was potently inhibited (IC 50 = 400–750 nM) by ibuprofenoyl-CoA and derivatives. Potency was positively correlated with inhibitor lipophilicity. AMACR was also inhibited by straight-chain and branched-chain acyl-CoA esters, with potency positively correlating with inhibitor lipophilicity. 2-Methyldecanoyl-CoAs were ca. 3-fold more potent inhibitors than decanoyl-CoA, demonstrating the importance of the 2-methyl group for effective inhibition. Elimination substrates and compounds with modified acyl-CoA cores were also investigated, and shown to be potent inhibitors. These results are the first to demonstrate structure–activity relationships of rational AMACR inhibitors and that potency can be predicted by acyl-CoA lipophilicity. The study also demonstrates the utility of the colorimetric assay for thorough inhibitor characterisation.

AB - α-Methylacyl-CoA racemase (AMACR; P504S) is a promising novel drug target for prostate and other cancers. Assaying enzyme activity is difficult due to the reversibility of the ‘racemisation’ reaction and the difficulties in the separation of epimeric products; consequently few inhibitors have been described and no structure–activity relationship study has been performed. This paper describes the first structure–activity relationship study, in which a series of 23 known and potential rational AMACR inhibitors were evaluated. AMACR was potently inhibited (IC 50 = 400–750 nM) by ibuprofenoyl-CoA and derivatives. Potency was positively correlated with inhibitor lipophilicity. AMACR was also inhibited by straight-chain and branched-chain acyl-CoA esters, with potency positively correlating with inhibitor lipophilicity. 2-Methyldecanoyl-CoAs were ca. 3-fold more potent inhibitors than decanoyl-CoA, demonstrating the importance of the 2-methyl group for effective inhibition. Elimination substrates and compounds with modified acyl-CoA cores were also investigated, and shown to be potent inhibitors. These results are the first to demonstrate structure–activity relationships of rational AMACR inhibitors and that potency can be predicted by acyl-CoA lipophilicity. The study also demonstrates the utility of the colorimetric assay for thorough inhibitor characterisation.

KW - Drug lipophilicity

KW - Enzyme inhibitors

KW - Rational drug design

KW - Structure-activity relationships

KW - α-Methylacyl-CoA racemase (AMACR, P504S)

UR - http://www.scopus.com/inward/record.url?scp=85046647493&partnerID=8YFLogxK

U2 - 10.1016/j.bioorg.2018.04.024

DO - 10.1016/j.bioorg.2018.04.024

M3 - Article

VL - 79

SP - 145

EP - 154

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

ER -